Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daratumumab Infusion Acceleration

NCT02944565 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.

NCT NCT02944565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02944565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daratumumab Infusion Acceleration
Lead sponsor
Ohio State University Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2017
Completion date
July 20, 2017
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma